The modulation of pathways involved in cancer metastasis (MMP9), inflammation (PTGS2), cell survival (AKT1), and DNA repair (PARP1) suggests that these compounds could serve as multitargeted therapies, providing an advantage over single-target drugs [46]. This evidence concerns the gene PTGS2 and cancer.